Differences in δ- and μ-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects
The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Blockade of brain mu-opioid receptor (mu-OR) and delta-opioid receptor (delta-OR) was investigated in recently abstinent alcohol-dependent subjects (N=21) maintained on naltrexone. Subjects completed a 19-day inpatient protocol, which included alcohol abstinence followed by naltrexone treatment (50 mg) on days 15-19. Blood samples were collected after the first administration of naltrexone to evaluate serum levels of naltrexone and 6-beta-naltrexol. Regional brain mu-OR binding potential (BP) and delta-OR Ki was measured using [11C]carfentanil (CAR) positron emission tomography (PET) and [11C]methyl naltrindole ([11C]MeNTI) PET, respectively, before (day 5) and during naltrexone treatment (day 18). Naltrexone inhibition of [11C]CAR BP was near maximal across all brain regions of interest with little variability across subjects (mean+SD% inhibition=94.9+4.9%). Naltrexone only partially inhibited the [11C]MeNTI Ki and there was more variability across subjects (mean+SD% inhibition=21.1+14.49%). Peak serum levels of naltrexone were positively correlated with % inhibition of delta-OR Ki in neocortex and basal ganglia. Peak serum levels of naltrexone were not correlated with % inhibition of mu-OR BP. Peak levels of 6-beta-naltrexol were not significantly correlated with % inhibition of mu-OR BP or delta-OR Ki. Thus, the FDA recommended therapeutic dose of naltrexone was sufficient to produce near complete inhibition of the mu-OR in recently abstinent alcohol dependent subjects. The lower percent inhibition of delta-OR and greater variability in delta-OR blockade by naltrexone across subjects may contribute to individual differences in treatment outcomes to naltrexone. Further investigations on the relationship between individual differences in delta-OR blockade by naltrexone and clinical outcomes should be explored.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“following steady-state oral administration, naltrexone achieves approximately 95% mu opioid receptor occupancy”
From Maintenance Medication for Opiate Addiction: The Foundation of Recovery (2012) · cites this paper as [122]
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Subjects completed the Clinical Institute Withdrawal Assessment-Alcohol Revised (CIWA-Ar) (Sullivan et al, 1989), 3–4 times each day for the first 5 days.”
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Bucholz, K. K., Cadoret, R., Cloninger, C. R., Dinwiddie, S. H., Hesselbrock, V. M., Nurnberger, J. I., Reich, T., Schmidt, I., & Schuckit, M. A. (1994) · Journal of Studies on Alcohol · doi:10.15288/jsa.1994.55.149 · Cited by 1,757
Davis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Alcohol dependence syndrome: Measurement and validation.
Skinner, H. A., & Allen, B. A. (1982) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.91.3.199 · Cited by 1,061
Research works printed but not linked: 1
- Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL et al (1996). Imaging of delta opioid receptors in human brain by N1′- ([11C]methyl)naltrindole and PET. Synapse 24: 19–28. · DOI · Paper page
Cited by
The changing opioid crisis: development, challenges and opportunities
Volkow, N. D., & Blanco, C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0661-4 · Cited by 522
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Alcohol and the Human Brain: A Systematic Review of Different Neuroimaging Methods
Bühler, M., & Mann, K. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01540.x · Cited by 310
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches
Peciña, M., Karp, J. F., Mathew, S., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J.-K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0117-2 · Cited by 190
McCluskey, S. P., Plisson, C., Rabiner, E. A., & Howes, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04488-0 · Cited by 120
Mann, K., Lemenager, T., Hoffmann, S., Reinhard, I., Hermann, D., Batra, A., Berner, M., Wodarz, N., Heinz, A., Smolka, M. N., et al. (2013) · Addiction Biology · doi:10.1111/adb.12012 · Cited by 116
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00172.x · Cited by 113
Opioids and social bonding: naltrexone reduces feelings of social connection
Inagaki, T. K., Ray, L. A., Irwin, M. R., Way, B. M., & Eisenberger, N. I. (2016) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsw006 · Cited by 105
Low-dose naltrexone for disease prevention and quality of life
Brown, N., & Panksepp, J. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.06.048 · Cited by 117
Ziauddeen, H., Chamberlain, S. R., Nathan, P. J., Koch, A., Maltby, K., Bush, M., Tao, W. X., Napolitano, A., Skeggs, A. L., Brooke, A. C., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.154 · Cited by 103
Weerts, E. M., Wand, G. S., Kuwabara, H., Munro, C. A., Dannals, R. F., Hilton, J., Frost, J. J., & McCaul, M. E. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01565.x · Cited by 98
Self-citationMann, K., Kiefer, F., Smolka, M., Gann, H., Wellek, S., Heinz, A., & and the PREDICT Study research team (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00884.x · Cited by 93
Naltrexone: Not Just for Opioids Anymore
Sudakin, D. L. (2015) · Journal of Medical Toxicology · doi:10.1007/s13181-015-0512-x · Cited by 103
Margolis, E. B., Fields, H. L., Hjelmstad, G. O., & Mitchell, J. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4569-08.2008 · Cited by 87
Schacht, J. P., Anton, R. F., Voronin, K. E., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.195 · Cited by 91
The role of the opioid system in alcohol dependence
Nutt, D. J. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113504017 · Cited by 85
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2134739 · Cited by 86
Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, B. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510366857 · Cited by 83
George, D. T., Herion, D. W., Jones, C. L., Phillips, M. J., Hersh, J., Hill, D., Heilig, M., Ramchandani, V. A., Geyer, C., Spero, D. E., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1704-3 · Cited by 74
Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K. F., Roche, D., Leventhal, A. M., SHOPTAW, S. J., Heinzerling, K. G., London, E. D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.83 · Cited by 84
Weber, S. C., Beck‐Schimmer, B., Kajdi, M.-E., Müller, D., Tobler, P. N., & Quednow, B. B. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.113 · Cited by 87
Burns, J. A., Kroll, D. S., Feldman, D. E., Liu, C. K., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00626 · Cited by 79
Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders
Niciu, M. J., & Arias, A. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0096-4 · Cited by 67
Weerts, E. M., McCaul, M. E., Kuwabara, H., Yang, X., Xu, X., Dannals, R. F., Frost, J. J., Wong, D. F., & Wand, G. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s146114571200017x · Cited by 69
Self-citationWilliams, T. A., Davies, S., Taylor, L. G., Daglish, M. R. C., Hammers, A., Brooks, D. J., Nutt, D. J., & Lingford-Hughes, A. R. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.06.007 · Cited by 78
King, A. C., Cao, D., O’Malley, S. S., Kranzler, H. R., Cai, X., de Wit, H., Matthews, A. K., & Stachoviak, R. J. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182676956 · Cited by 75
Cant, R., Dalgleish, A. G., & Allen, R. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00809 · Cited by 77
Oslin, D. W., Lynch, K. G., Pettinati, H. M., Kampman, K. M., Gariti, P., Gelfand, L., Ten Have, T., Wortman, S., Dundon, W., Dackis, C., et al. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00698.x · Cited by 64
Oliva, V., Hartley-Davies, R., Moran, R., Pickering, A. E., & Brooks, J. C. (2022) · eLife · doi:10.7554/elife.71877 · Cited by 69
Ray, L. A., Green, R., Roche, D. J. O., Magill, M., & Bujarski, S. (2019) · Addiction Biology · doi:10.1111/adb.12747 · Cited by 59
Ashenhurst, J. R., Bujarski, S., & Ray, L. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.019 · Cited by 59
Mouaffak, F., Leite, C., Hamzaoui, S., Benyamina, A., Laqueille, X., & Kebir, O. (2017) · European Addiction Research · doi:10.1159/000480539 · Cited by 52
Hansson, A. C., Gründer, G., Hirth, N., Noori, H. R., Spanagel, R., & Sommer, W. H. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.010 · Cited by 59
Laeng, B., Garvija, L. K., Løseth, G. E., Eikemo, M., Ernst, G., & Leknes, S. (2021) · Consciousness and Cognition · doi:10.1016/j.concog.2021.103105 · Cited by 56
Blocking opioids attenuates physical warmth-induced feelings of social connection.
Inagaki, T. K., Irwin, M. R., & Eisenberger, N. I. (2015) · Emotion · doi:10.1037/emo0000088 · Cited by 52
Interactions Between Alcohol and the Endocannabinoid System
Kunos, G. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14306 · Cited by 56
Langleben, D. D., Ruparel, K., Elman, I., Loughead, J., Busch, E. L., Cornish, J., Lynch, K. G., Nuwayser, E. S., Childress, A. R., & O’Brien, C. P. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00462.x · Cited by 54
Nathan, P. J., O'Neill, B. V., Bush, M. A., Koch, A., Tao, W. X., Maltby, K., Napolitano, A., Brooke, A. C., Skeggs, A. L., Herman, C. S., et al. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011399577 · Cited by 47
Ray, L. A., Courtney, K. E., Ghahremani, D. G., Miotto, K. A., Brody, A. L., & London, E. D. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3519-0 · Cited by 50
Cabanas, H., Muraki, K., Staines, D., & Marshall‐Gradisnik, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02545 · Cited by 51
Trøstheim, M., Eikemo, M., Haaker, J., Frost, J. J., & Leknes, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01416-z · Cited by 49
Self-citationAshok, A. H., Myers, J., Marques, T. R., Rabiner, E. A., & Howes, O. D. (2019) · Nature Communications · doi:10.1038/s41467-019-12366-4 · Cited by 49
Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?
Colom, M., Vidal, B., & Zimmer, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00255 · Cited by 50
The delta opioid receptor tool box
Vicente‐Sánchez, A., Segura, L., & Pradhan, A. A. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.028 · Cited by 49
A Survey of Molecular Imaging of Opioid Receptors
Cumming, P. D., Marton, J., Lilius, T. O., Olberg, D. E., & Rominger, A. (2019) · Molecules · doi:10.3390/molecules24224190 · Cited by 46
Neuroimaging the Effectiveness of Substance Use Disorder Treatments
Cabrera, E. A., Wiers, C. E., Lindgren, E., Miller, G., Volkow, N. D., & Wang, G. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9680-y · Cited by 46
Stress and pain: modality-specific opioid mediation of stress-induced analgesia
Al’Absi, M., Nakajima, M., & Bruehl, S. P. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02401-4 · Cited by 43
Inagaki, T. K., Hazlett, L. I., & Andreescu, C. (2020) · Journal of Experimental Psychology General · doi:10.1037/xge0000674 · Cited by 44
Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer
Szczepaniak, A., Fichna, J., & Zielińska, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0699-1 · Cited by 46
The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia
Jackson, D., Singh, S., Zhang‐James, Y., Faraone, S. V., & Johnson, B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.593842 · Cited by 44
Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse
Lê, A. D., Funk, D. R., Lo, S., & Coen, K. M. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3541-2 · Cited by 42
Cabanas, H., Muraki, K., Eaton-Fitch, N., Staines, D., & Marshall‐Gradisnik, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687806 · Cited by 44
Fentanyl and Other Opioid Use Disorders: Treatment and Research Needs
Volkow, N. D., & Blanco, C. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230273 · Cited by 44
Endogenous opiates and behavior: 2008
Bodnar, R. J. (2009) · Peptides · doi:10.1016/j.peptides.2009.09.027 · Cited by 49
Opioid modulators for alcohol dependence
Hillemacher, T., Heberlein, A., Muschler, M. A. N., Bleich, S., & Frieling, H. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.592139 · Cited by 41
Roche, D. J. O., Ray, L. A., Yardley, M. M., & King, A. C. (2016) · Current Addiction Reports · doi:10.1007/s40429-016-0081-3 · Cited by 42
Machine-learning repurposing of DrugBank compounds for opioid use disorder
Feng, H., Jiang, J., & Wei, G. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106921 · Cited by 39
Kim, S. J., Zheng, M., Nabulsi, N., Labaree, D. C., Ropchan, J. R., Najafzadeh, S., Carson, R. E., Huang, Y. H., & Morris, E. D. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118877 · Cited by 38
Highly multiplexed design of an allosteric transcription factor to sense new ligands
Nishikawa, K. K., Chen, J., Acheson, J. F., Harbaugh, S. V., Huss, P., Frenkel, M. P. C., Novy, N., Sieren, H. R., Lodewyk, E. C., Lee, D. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54260-8 · Cited by 36
Greenwald, M. K. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.08.003 · Cited by 34
Schick, M. R., Spillane, N. S., & Hostetler, K. L. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14440 · Cited by 35
Altamirano, L. J., Fields, H. L., D’Esposito, M., & Boettiger, C. A. (2011) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01535.x · Cited by 36
Turton, S., Myers, J. F., Mick, I., Colasanti, A., Venkataraman, A. V., Durant, C. F., Waldman, A. D., Brailsford, A. D., Parkin, M. C., Dawe, G., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0107-4 · Cited by 35
Mobile alcohol biosensors and pharmacotherapy development research
Roberts, W., & McKee, S. A. (2018) · Alcohol · doi:10.1016/j.alcohol.2018.07.012 · Cited by 32
Hillmer, A. T., Mason, G. F., Fucito, L. M., O’Malley, S. S., & Cosgrove, K. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12893 · Cited by 34
de Abreu, M. S., Giacomini, A. C. V. V., Demin, K. A., Galstyan, D. S., Zabegalov, K. N., Kolesnikova, T. O., Amstislavskaya, T. G., Strekalova, T. V., Petersen, E. V., & Kalueff, A. V. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173205 · Cited by 37
King, A. C., Cao, D., Zhang, L., & O’Malley, S. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.025 · Cited by 31
Medications for unhealthy alcohol use: across the spectrum.
O’Malley, S. S., & O’Connor, P. G. (2011) · PubMed Central · Cited by 38
Weerts, E. M., Wand, G. S., Kuwabara, H., Xu, X., Frost, J. J., Wong, D. F., & McCaul, M. E. (2012) · Addiction Biology · doi:10.1111/adb.12022 · Cited by 33
Self-citationOpioid Modulation of Oxytocin Release
Morris, M. S., Domino, E. F., & Domino, S. E. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010361256 · Cited by 32
Grodin, E. N., & Ray, L. A. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14167 · Cited by 31
Naltrexone in the Treatment of Alcohol Dependence
Unterwald, E. M. (2008) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318182b20f · Cited by 32
Focusing on the Opioid System for Addiction Biomarker Discovery
Belzeaux, R., Lalanne, L., Kieffer, B. L., & Lutz, P.-E. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.004 · Cited by 28
Eaton-Fitch, N., Preez, S. D., Cabanas, H., Muraki, K., Staines, D., & Marshall‐Gradisnik, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03297-8 · Cited by 27
Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?
Kleczkowska, P., Smaga, I., Filip, M., & Bujalska‐Zadrożny, M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9555-7 · Cited by 29
Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia
Choubey, A., Girdhar, K., Kar, A. K., Kushwaha, S., Yadav, M. K., Ghosh, D., & Mondal, P. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013484 · Cited by 29
Medications Development for Treatment of Opioid Use Disorder
Townsend, E. A., Negus, S. S., & Banks, M. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039263 · Cited by 26
The molecular neurobiology and neuropathology of opioid use disorder
Blackwood, C. A., & Cadet, J. L. (2021) · Current Research in Neurobiology · doi:10.1016/j.crneur.2021.100023 · Cited by 26
Setiawan, E., Pihl, R. O., Benkelfat, C., & Leyton, M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.99 · Cited by 26
Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving
de Laat, B., Nabulsi, N., Huang, Y. H., O’Malley, S. S., Froehlich, J. C., Morris, E. D., & Krishnan‐Sarin, S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0811-8 · Cited by 21
Wand, G. S., Weerts, E. M., Kuwabara, H., Wong, D. F., Xu, X., & McCaul, M. E. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00430.x · Cited by 21
Self-citationFlorence, L. L. A., Lassi, D. L. S., Kortas, G. T., Lima, D. R., Périco, C. D. A.-M., de Andrade, A. G., Torales, J. C., Ventriglio, A., Berardis, D. D., Aquino, J. P. D., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12030386 · Cited by 22
Korpi, E. R., Linden, A.-M., Hytönen, H. R., Paasikoski, N., Vashchinkina, E., Dudek, M., Herr, D. R., & Hyytiä, P. (2016) · Addiction Biology · doi:10.1111/adb.12393 · Cited by 18
Krieter, P. A., Gyaw, S., Chiang, C. N., Crystal, R., & Skolnick, P. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1384 · Cited by 18
Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
Ciwun, M., Tankiewicz‐Kwedlo, A., & Pawlak, D. (2024) · Cancers · doi:10.3390/cancers16061240 · Cited by 19
Al’Absi, M., Nakajima, M., DeAngelis, B. N., Grant, J. E., King, A. C., Grabowski, J. G., Hatsukami, D. K., & ALLEN, S. S. (2020) · Stress · doi:10.1080/10253890.2020.1823367 · Cited by 18
Opioid antagonism modulates wanting-related frontostriatal connectivity
Soutschek, A., Weber, S. C., Kahnt, T., Quednow, B. B., & Tobler, P. N. (2021) · eLife · doi:10.7554/elife.71077 · Cited by 15
Feng, H., Wang, R., Zhan, C., & Wei, G. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01053 · Cited by 15
Simon, N., & von Fabeck, K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1660323 · Cited by 13
Wand, G. S., Weerts, E. M., Kuwabara, H., Wong, D. F., Xu, X., & McCaul, M. E. (2012) · Alcohol · doi:10.1016/j.alcohol.2012.04.006 · Cited by 13
Self-citationMoeller, S. J., Beebe-Wang, N., Schneider, K. E., Konova, A. B., Parvaz, M. A., Alia‐Klein, N., Hurd, Y. L., & Goldstein, R. Z. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.004 · Cited by 14
Multiple Linear Analysis Methods for the Quantification of Irreversibly Binding Radiotracers
Kim, S. J., Lee, J. S., Kim, Y. K., Frost, J., Wand, G. S., McCaul, M. E., & Lee, D. S. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.84 · Cited by 12
Self-citationNaik, S., Belfort‐DeAguiar, R., Sejling, A., Szepietowska, B., & Sherwin, R. S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12855 · Cited by 11
Seo, S., Kim, S., Lee, D. S., & Lee, J. S. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-014-1465-9 · Cited by 11
Self-citationElmosalamy, A., Sirohi, A., Moustafa, A., Masoud, O., Hassett, L. C., Kolla, B. P., & Singh, B. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112789 · Cited by 11
Evaluation and treatment of compulsive sexual behavior: current limitations and potential strategies
Zhu, L., Ma, W., Zhang, R., Wang, C., Song, B., Cao, Y., & Li, G. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621136 · Cited by 9
Tan, L. A., Gajipara, N., Sun, L., Bacolod, M. D., Zhou, Y., Namchuk, M., & Cunningham, J. I. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s373195 · Cited by 8
Metadata
- Authors
- Weerts, E. M., Kim, Y. K., Wand, G. S., Dannals, R. F., Lee, J. S., Frost, J. J., & McCaul, M. E.
- Affiliations
- Johns Hopkins University (US)
- Seoul National University (KR)
- Corresponding author
- Weerts, Elise M
- Venue
- Neuropsychopharmacology
- Published
- 2007-05-09
- Volume
- 33
- Issue
- 3
- Pages
- 653-665
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2154071856
- Cited by
- 147
- References
- 93
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 9 · 2019: 15 · 2018: 9 · 2017: 2 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 7 · 2012: 14
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (AA11855, R01AA011855, R37AA012303, AA12303, AA11872, R01AA011872)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- naltrexone, mu-opioid receptor, delta opioid receptor, opioid receptor blockade, alcoholism, alcohol abstinence, [11C]carfentanil, individual differences in treatment response, brain receptor binding
- MeSH terms
- Adult, Alcoholism, Analgesics, Opioid, Data Interpretation, Statistical, Female, Fentanyl, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Substance Withdrawal Syndrome, Temperance, Receptors, Opioid, mu, Receptors, Opioid, delta, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.